The investigational mannose-1-phosphate replacement therapy aims to restore metabolic function and improve neurological outcomes in pediatric and adult patients.
Earlier in026, Revolution Medicines announced that the FDA granted Breakthrough Therapy Designation to RASONQUE (daraxonrasib ...
21h
FDA Grants Breakthrough Therapy Designation to Glycomine’s GLM101 for the Treatment of PMM2-CDG
Designation is based on clinical evidence from Phase 2a, including improvements in ataxia and other clinical measures after 24 weeks of GLM101 treatment ...
Nipocalimab 15mg/kg improved ClinESSDAI score compared with placebo (treatment difference -2.65; [90% CI, -4.03, -1.28]; P =.002). The Food and Drug Administration (FDA) has granted Breakthrough ...
Orchestra BioMed has announced that the FDA has granted Breakthrough Device Designation for its atrioventricular interval modulation (AVIM) therapy, aimed at treating over 7.7 million U.S. patients ...
A single jab of a breakthrough gene therapy could reverse hearing loss in people within weeks, according to new research. The cutting-edge therapy improved hearing in children and adults with ...
Encellin Partners with Breakthrough T1D to Advance Immune-Protected Cell Therapy for Type 1 Diabetes
The new trial (NCT07680673) will bring ENCRT-103-hPI, Encellin's immune-protected implant configuration, into the clinic. ENCRT-103-hPI builds on the successful completion of NCT06408311, Encellin's ...
The FDA has granted breakthrough therapy designation to the DT120 Orally Disintegrating Tablet after preliminary clinical evidence showed significant improvements in treating major depressive disorder ...
Therapeutic gene transfer to specific brain regions in animal models of Alzheimer's disease has uncovered multiple potential treatment approaches that deserve to be considered as candidates for ...
A study evaluating a pioneering lentivirus (LV)-mediated gene therapy trial for classical Fabry disease showed promising results over five years, indicating a potential breakthrough in treatment for ...
HIGH POINT, N.C., April 13, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for ...
The FDA has granted breakthrough therapy designation to daraxonrasib (Rasonque), an oral RAS(ON) multi-selective inhibitor, in combination with gemcitabine and nab-paclitaxel (GnP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results